CHO

Applied Biomics Launches Anti-Host Cell Protein (HCP) Antibodies with > 95% Coverage

Retrieved on: 
Thursday, February 29, 2024

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.

Key Points: 
  • Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.
  • View the full release here: https://www.businesswire.com/news/home/20240228749573/en/
    Antibody Coverage of Applied Biomics' Anti-CHO Antibody by 2D Western Blot (WB).
  • Following are highlights of Applied Biomics’ HCP Antibodies:
    High HCP coverage: Detects well over 2500 (up to ~5000) low and high molecular weight (LMW & HMW) HCPs, with > 95% overall HCP coverage and > 90% each quadrant coverage.
  • With our leading HCP antibody coverage services , customers can now test Applied Biomics’ HCP antibody against their process specific HCPs, or compare with other HCP antibodies to find a better fit.

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Retrieved on: 
Thursday, February 29, 2024

The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.

Key Points: 
  • The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.
  • Combining Charles River's industry-leading experience in antibody discovery services, safety, and analytics with Wheeler's Portable CMC® platform will accelerate therapeutic discovery to Investigational New Drug (IND) submission timelines.
  • Wheeler Bio's mission is to solve translational challenges inherent in advancing from discovery to CMC development and early-clinical trial material supply.
  • Jesse McCool, CEO and Co-Founder of Wheeler Bio, stated, "Wheeler is excited to expand our relationship with Charles River and to link with their discovery organization.

OHAI.AI LAUNCHES AI VIRTUAL ASSISTANT TO REVOLUTIONIZE HOME AND PERSONAL ORGANIZATION IN SUPPORT OF CHIEF HOUSEHOLD OFFICERS

Retrieved on: 
Monday, January 22, 2024

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- Ohai.ai, a platform leveraging AI to revolutionize caregiving and improve the lives of families, launches today led by Sheila Lirio Marcelo, Founder and former CEO of Care.com. Ohai.ai has raised $6 million in a seed financing round co-led by Eniac Ventures and LifeX Ventures.

Key Points: 
  • Ohai.ai's AI virtual assistant, O, aims to revolutionize home and personal organization, alleviating the mental load of Chief Household Officers.
  • "Balancing family and career has been an ongoing challenge in my life," said Lirio Marcelo, Co-founder and CEO of Ohai.ai.
  • Based on feedback from numerous Chief Household Officers, Ohai is priced affordably at under $30 per month.
  • O can help shoulder the cognitive load so you are no longer solely responsible for managing the family calendar and to-do list.

Optimizing Monoclonal Antibody Production: Temperature and Osmolality's Impact, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, January 18, 2024

TORONTO, Jan. 18, 2024 /PRNewswire-PRWeb/ -- Over the past two decades, the biopharmaceutical market has expanded, with monoclonal antibodies exhibiting a 26 percent higher approval rate than other drugs. The market value of monoclonal antibodies alone is expected to reach more than $300 billion USD by 2025. Monoclonal antibodies are recombinant proteins that are extracellularly secreted by mammalian cells, such as Chinese hamster ovary (CHO) cells. Advances in monoclonal antibody production technology and manufacturing strategies have led to increased yield, which is, however, accompanied by increased levels of impurities, such as host cell proteins (HCPs).

Key Points: 
  • In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies.
  • Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant.
  • The featured speaker will discuss how temperature and osmolality in the cell culture can be optimized, seeking improved monoclonal antibody production efficiency.
  • Join this webinar to investigate the effects of simultaneously adjusting temperature and osmolality on the generation of HCPs, antibody yield and cell growth.

Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics

Retrieved on: 
Wednesday, December 6, 2023

SAN DIEGO, Dec. 6, 2023 /PRNewswire/ -- Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium protein expression technology, 2G UNic®. This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.

Key Points: 
  • This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.
  • For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets.
  • Frank Pieper, CEO of ProteoNic commented: "We are pleased that we can contribute to achieving the best results for Abzena and its customers.
  • Under the agreement, Abzena gains worldwide, non-exclusive commercial rights for the application of ProteoNic's 2G UNic® premium vector technology in the development of high-yielding CHO cell lines.

Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics

Retrieved on: 
Wednesday, December 6, 2023

SAN DIEGO, Dec. 6, 2023 /PRNewswire/ -- Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium protein expression technology, 2G UNic®. This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.

Key Points: 
  • This state-of-the-art vector technology will significantly improve the production of high-yielding CHO cell lines for Abzena's customers.
  • For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets.
  • Frank Pieper, CEO of ProteoNic commented: "We are pleased that we can contribute to achieving the best results for Abzena and its customers.
  • Under the agreement, Abzena gains worldwide, non-exclusive commercial rights for the application of ProteoNic's 2G UNic® premium vector technology in the development of high-yielding CHO cell lines.

Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC

Retrieved on: 
Wednesday, November 8, 2023

The organizations are collaborating to provide a premiere service experience for Alloy partners requiring CMC development services from Wheeler as a high-quality, reliable CMC service provider for development and GMP manufacturing.

Key Points: 
  • The organizations are collaborating to provide a premiere service experience for Alloy partners requiring CMC development services from Wheeler as a high-quality, reliable CMC service provider for development and GMP manufacturing.
  • Alloy and Wheeler Bio are offering a premium service experience for existing and future ATX-Gx platform users and Alloy Discovery Service partners who also contract Portable CMC™ development services with Wheeler Bio.
  • Introducing Wheeler's Phase™ offering, where partners of both Alloy and Wheeler will receive the following preferred services:
    Dollar-for-dollar reductions in Alloy commercial milestones matching Wheeler Portable CMC™ services contracted for 'Lead-to-Tox' and 'Lead-to-Clinic' programs.
  • Free CMC consulting services to advise ecosystem partners on the translation from discovery to CMC development.

Osmolality Analysis in Bioprocessing: From Theory to Practice, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 6, 2023

TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.

Key Points: 
  • Attendees will learn about using osmolality analysis in Chinese hamster ovary (CHO) cell health studies.
  • The featured speakers will discuss current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing.
  • TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production.
  • Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Retrieved on: 
Wednesday, October 25, 2023

BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

Key Points: 
  • “The preclinical data showed ORX750 achieved maximal wake times and suppressed cataplexy at 0.1 mg/kg, the lowest oral dose tested in the DTA mouse model.
  • Notably, this activity was observed in both the DTA and Atax mouse models that recapitulate NT1 symptoms in humans.
  • Fluorescent imaging plate reader (FLIPR) assay with Chinese hamster ovary (CHO) cells stably expressing recombinant human OX1R or OX2R; OXA EC50 at hOX2R = 0.035 nM.
  • As measured by electroencephalogram (EEG) and electromyogram (EMG) with concurrent video in DTA and Atax mouse models.

Quantifying Genetic Stability and Quality Control of Multiple Integrations of Orthogonal Transposases, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 25, 2023

TORONTO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into transposase-mediated genome engineering, genetic quality control (QC) and stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology. Genes encoding biotherapeutic proteins can stably be introduced into mammalian genomes by several different approaches. The transposon-based platform avoids major challenges presented by random integration or viral-based delivery systems.

Key Points: 
  • In this free webinar, learn about transposase-mediated genome engineering, genetic quality control and ensuring the genetic stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.
  • TORONTO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into transposase-mediated genome engineering, genetic quality control (QC) and stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.
  • Furthermore, by comparing the TLA data of different timepoints they were able to evaluate the genetic stability and integrity of the transposons.
  • Join this webinar to learn about transposase-mediated genome engineering, genetic quality control and ensuring the genetic stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.